ALOX5 and cervical cancer: The evaluation of the effects of this 3-arylisocoumarin at 50 μM on 5-Lipoxygenase (5-LOX) activity and the level of prostaglandin E2 (PGE2) in HeLa cervical cancer cells, indicated inhibition of 5-LOX and PGE2 production with IC50 of 4.6 and 6.3 mM, respectively, thereby demonstrating important anti-inflammatory effects [21].